Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

AstraZeneca's Medimmune subsidiary announced a collaboration this morning with UK company Immunocore that will focus on the development of cancer therapeutics.

The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to tackle tumours.

The deal potentially covers a number of targets, with AZ offering an upfront fee of $20m and up to $300m in development and milestone payments per programme, plus royalties if any of the therapies reach the market.

Immunocore also has collaborations in place with GlaxoSmithKline and Roche/Genentech, as well as its own melanoma therapy in phase II testing.

Article by
Phil Taylor

9th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...